Marizyme, Inc. Announces FDA Clearance for Flagship Product, DuraGraft™ DuraGraft is the first and only FDA cleared medical device for use as an intra-operative vascular conduit storage and flushing solution used during CABG surgeries $Marizyme, Inc.(MRZM)$ $Marizyme, Inc.(MRZM)$ $Marizyme, Inc.(MRZM)$ JUPITER, FL, Oct. 06, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - Marizyme, Inc. (OTCQB:MRZM) (“Marizyme” or the “Company”), a global medical technology company focused on the development of products to address unmet clinical needs, today announced that it was granted a de novo from the U.S. Food and Drug Administration (FDA) for its first in-class product,